Background. Hepatitis A and B vaccines are effective in preventing superinfection and sequelae in patients with chronic hepatitis B or C. We describe immunity and vaccination against hepatitis A and B in chronic hepatitis patients from the US Chronic Hepatitis Cohort Study.
Adjusting for asymptomatic cases and underreporting, 35 000 cases of acute hepatitis B infection and 17 000 cases of acute hepatitis A infection occurred in the United States in 2010 [1] . Coinfection with chronic hepatitis C (CHC) and chronic hepatitis B (CHB) heightens an individual's risk for progressive liver disease and hepatocellular carcinoma [2, 3] . There is evidence of an increased risk of acute liver failure in CHC patients who have a superimposed acute hepatitis A infection [4, 5] . Hepatitis A infection in CHB patients carries a higher case fatality rate [6] . Therefore, the portion of the estimated 2.7-3.9 million people with CHC and 800 000-1.4 million people with CHB in the United States without prior immunity or history of vaccination are potentially vulnerable to sequelae of superinfection with these hepatotropic vaccine-preventable viruses [7, 8] .
Hepatitis A and B vaccines are effective vaccines that can prevent superinfection in patients with CHB or CHC infection. Guidelines for their use in such populations are not consistent. While some rely on clinicians to identify patients with chronic liver disease or risk factors for hepatitis B infection, others broadly recommend vaccination for all CHC and CHB patients without evidence of immunity [4, [9] [10] [11] . The definition of chronic liver disease is not included in the guidelines.
We describe the current recommendations for vaccination and the frequency of and factors related to immunity or vaccination and vaccination against hepatitis A in CHB and hepatitis A and B in CHC health plan members from US patients included in the Chronic Hepatitis Cohort Study (CHeCS).
METHODS
The CHeCS study population was drawn from 4 geographically disparate healthcare organizations: Kaiser Permanente Northwest (Portland, Oregon), Kaiser Permanente Hawaii (Honolulu, Hawaii), Henry Ford Health System (Detroit, Michigan), and Geisinger Health System (Danville, Pennsylvania). We identified CHB and CHC patients with healthcare utilization between 2006 and 2008 using an algorithm of hepatitis and chronic liver disease, International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes, and/or laboratory results (hepatitis C RNA alone or laboratory evidence of current hepatitis B [ positive hepatitis B surface antigen, hepatitis B e-antigen, or DNA serology]) as previously described [12] . All patients included in this analysis were confirmed to have CHB or CHC by chart review; we excluded patients coinfected with CHB and CHC. This analysis was restricted to health plan members with at least 12 months of continuous enrollment. All health plan and health record data were collected through 31 December 2010.
We used electronic laboratory records to determine immunity, and electronic medical (CVX codes, which include history of vaccination) and billing records (Current Procedural Terminology codes) for vaccination history. Patients were considered immune against hepatitis A if they had a positive hepatitis A antibody test (total hepatitis A antibody [anti-HA], immune from previous infection or vaccination). Evidence of immunity against hepatitis B was defined as a positive hepatitis B surface antibody (anti-HBs) (levels ≥10 mIU/mL) or a positive hepatitis B core antibody (anti-HBc, immune from previous infection). We considered patients to be vaccinated against hepatitis A or B with documentation of at least 1 dose of the respective vaccine.
Explanatory variables available in the medical record included age as of last encounter, sex, race, ethnicity, and length of time with a hepatitis B or C diagnosis. Median household income was estimated based on census tract data based on geocode. Duration of plan member coverage was reported as median years with standard deviation (SD). The severity of liver disease was classified as compensated cirrhotic, decompensated cirrhotic, or noncirrhotic based on ICD-9-CM codes as previously described [13] . The noncirrhotic group included those with no liver disease and those with no evaluation or documented ICD-9-CM code. In addition, the FIB-4 score was included as a noninvasive surrogate for liver fibrosis, validated against liver biopsy in these CHC and CHB cohorts [14, 15] . The FIB-4 score was calculated as age (years) × aspartate aminotransferase (U/L) / (platelet count (10 9 /L) × (alanine aminotransferase ½ (U/L)) and log-transformed for all analyses.
A logistic regression model was applied given the binary outcome of immune or not immune. Analyses began with testing for univariate variable effect, followed by multivariable modeling. Given varied data availability status among the sites, all multivariate analyses were adjusted by site of enrollment. The final model would retain variables with a P value <.05 and be assessed for the model goodness-of-fit (c-index). [17] evidence of immunity to hepatitis A and/or B, based on expert opinion [11] . The Advisory Committee on Immunization Practices (ACIP) recommends hepatitis A vaccine for susceptible patients with chronic liver disease but not routinely for CHB or CHC patients without chronic liver disease [4] . The American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver both recommend hepatitis A vaccine for all CHC patients with no evidence of preexisting antibody, but the AASLD similarly recommends vaccinating CHB patients with chronic liver disease [9, 16] . AASLD guidelines state that hepatitis B vaccine should be offered to CHC patients. The ACIP recommends hepatitis B vaccination of adults with chronic liver disease in addition to those at risk for infection by sexual exposure or exposure to blood [10] . The Physician Quality Reporting System quality indicator from the Centers for Medicare and Medicaid Services counts all CHC patients with at least 1 hepatitis A vaccine or documented immunity to hepatitis A [17] .
RESULTS

Review of Current Recommendations
Chronic Hepatitis B-Infected Patients
We identified 1635 CHB-infected patients ( Table 2) . Half the population (50%) was 40-59 years old, 49% were of Asian descent, and 55% were male. Most (78%) were classified as noncirrhotic. Among the 1635 patients, 978 (59.8%) had evidence of immunity or vaccination against hepatitis A infection, whereas 122 (7.5%) tested negative and were unvaccinated and 535 (32.7%) were neither tested for nor vaccinated against hepatitis A infection ( Figure 1A ). Among 1246 (76.2%) patients with no record of vaccination, 711 (57.1%) had an anti-HA test, and of these, 589 (82.8%) had a positive test. Of the 389 vaccinated, 242 (62.2%) received the complete hepatitis A vaccine series of 2 doses. In univariate analysis (Table 3) , the oldest patients (≥80 years old) were less likely to have immunity or vaccination than any other age group (17% compared with 53%-65% per 10-year age strata). Native American (43%) and black (42%) patients were less likely to have immunity or vaccination (vs 51%-66% in other ethnic groups 
Chronic Hepatitis C-Infected Patients
Of the 5328 CHC-infected patients identified, 75% were aged 50-69 years, 61% were male, and 63% were white. There was documented decompensated cirrhosis in 27% and compensated cirrhosis in 8%. Of the 5328 patients, 2998 (56.3%) had Patients with an income of <$30 000 had less immunity or vaccination than those ≥$30 000. Non-Hispanic patients (56%) were less likely to be protected than Hispanic patients (68%; P = .001). Black patients (44%) were least likely and Asian patients (73%) were most likely to have immunity or vaccination. Patients with compensated cirrhosis also had significantly more immunity or vaccination (64%) than those with no documented cirrhosis (55%; P < .001). After multivariable adjustment, compensated cirrhosis (OR, 1.52; 95% CI, 1.22-1.90 vs no cirrhosis), increased time of member coverage (OR, 1.08/year; 95% CI, 1.07-1.11), and increased FIB-4 score (log OR, 1.06 per 1-point increase; 95% CI, 1.04-1.09) were significantly associated with immunity or vaccination.
A total of 3150 of 5328 (59.1%) CHC patients had evidence of immunity or vaccination against hepatitis B infection, whereas 1003 (18.8%) tested negative and were unvaccinated and 1175 (22.1%) were neither tested for nor vaccinated against hepatitis B ( Figure 1C ). Of the 1871 vaccinated, 1275 (68.1%) received the complete hepatitis B vaccine series of 3 doses or shots. Among 3457 patients without evidence of vaccination, 2282 (66.0%) were tested for either anti-HBs or anti-HBc, and 1279 (56.0%) tested positive to either or both. Among 665 patients who tested negative for anti-HBs and had a test for anti-HBc, 304 (45.7%) had a positive test for anti-HBc only. Among 445 patients who tested positive for anti-HBs and had a test for antiHBc, 340 (76.4%) also had a positive anti-HBc result.
In univariate analysis (Table 3) , patients 30-39 and ≥80 years of age had the lowest rates of immunity (51% and 50%, respectively). In addition, patients without immunity or vaccination had a shorter duration of membership (mean, 104 [SD, 44] 
DISCUSSION
A small but significant percent of patients with CHC and CHB remain susceptible to infection with hepatitis A, and at least 19% of CHC patients are susceptible to hepatitis B infections across geographically diverse patients, despite access to care. Contrary to vaccination guidelines targeting patients with chronic liver disease, we did not observe a higher level of immunity or vaccination against hepatitis A among CHB patients with cirrhosis or among CHC patients with decompensated cirrhosis compared to those without cirrhosis. However, CHC patients with compensated cirrhosis were more likely to be immune or vaccinated against hepatitis A and hepatitis B, and those with decompensated cirrhosis more likely to be immune or vaccinated against hepatitis B than those without cirrhosis. To our knowledge, this is the first study to report hepatitis A immunity and vaccination for CHB patients in a US cohort. Evidence of hepatitis B immunity and vaccination was more modest among 88 256 CHC patients identified in the Department of Veterans Affairs (VA) Chronic Hepatitis C Clinical Case Registry (45.5% vs 59% in our study) [18] . Hepatitis A immunity was slightly higher (57.0%) in the VA CHC population. One major difference within the VA system was higher antibody testing rates: 82.2% for anti-HBs (vs 66.0% in our study) and 68.6% (vs 50.8% in our study) for anti-HA antibody. In the VA Palo Alto Health Care System, 72% and 78% of 2968 hepatitis C-positive patients were tested for hepatitis A and B, respectively, and 70.5% and 69.6% were immune or vaccinated for hepatitis A and B, respectively [19] . A 2005 study in the VA New York Harbor Healthcare System found that 53.7% of 1193 hepatitis C RNA-positive patients were tested for hepatitis A and only 34.6% were immune or vaccinated, suggesting that there have been improvements over time in testing and vaccinating patients with chronic hepatitis [20] .
The overall incidence of acute hepatitis A and acute hepatitis B is at an all-time low in the United States, with incidence rates Foodborne hepatitis A outbreaks still occur, including a large outbreak in 2013 that was associated with at least 162 confirmed cases and 71 hospitalizations [21] . However, in our population, a large proportion of unvaccinated CHC patients tested for immunity were susceptible to hepatitis A infection (38%) or hepatitis B infection (44%). In addition, CHC patients may exhibit behaviors that put them at higher risk for hepatitis B infection such as injection drug use or unsafe sex practices. We excluded patients known to be coinfected with CHC and CHB. Because patients with chronic viral hepatitis or other chronic liver disease may be particularly susceptible to superinfection with other hepatotropic viruses, algorithms have been published to guide testing and vaccination of patients with chronic liver disease [9, 22, 23] . Patients with chronic liver disease or CHB/CHC infection have lower initial response to hepatitis A vaccine but overall respond well to the 2 vaccine series [6] . Similarly, lower seroprotection after hepatitis B vaccination is observed in patients with CHC infection [24, 25] . It is likely that many or most patients receive their vaccine prior to progression to advanced liver disease, given that 65% of CHC and 78% of CHB patients in our study were categorized as noncirrhotic, so we expect their response to be similar to healthy controls. We observed a higher rate of hepatitis A and B immunity among our CHC patients with cirrhosis. Given the ambiguity around the definition of chronic liver disease in the published vaccination recommendations, and considering that the majority of both CHB and CHC patients are noncirrhotic and receive limited or late follow-up care, there may be missed opportunities to vaccinate before vaccine response rates drop [26] .
We observed similar initiation of hepatitis A (34.4%) and hepatitis B vaccination (33.2%) in CHC patients. With the availability of a licensed combination hepatitis A/B vaccine, it should not be difficult to attain hepatitis B vaccine initiation at levels similar to hepatitis A vaccination. In addition, series completion rates were similar for hepatitis B vaccine (68%), which requires 3 injections, and hepatitis A vaccine (70%), which requires 2 injections. We chose to consider the 38% of unvaccinated patients with anti-HBc alone as immune, based on prior studies that show that high-risk patients with isolated anti-HBc are protected from reinfection with hepatitis B virus [27] . This assumption may underestimate the number of patients who are susceptible to hepatitis B infection. The presence of at least 10 mIU/mL of anti-HBs is the standard correlate of immunity, but the response to a hepatitis B vaccine challenge dose implies immunity even at low or undetectable anti-HBs [28] . The presence of antiHBc indicates prior exposure, and immunologic memory likely provides immunity if the patient is reexposed [29] . Nevertheless, AASLD practice guidelines recommend a full hepatitis B vaccine series in patients who are anti-HBc positive and antiHBs negative [30] . At a minimum, a booster dose may be needed in these patients [23, 31] .
Among those tested for anti-HA, 60% of unvaccinated CHC and 81% of unvaccinated CHB patients tested positive. For comparison, based on National Health and Nutrition Examination Survey data, an estimated 40% of the US population aged ≥30 years is anti-HA positive (unpublished data, Centers for Disease Control and Prevention). The higher rates of protection observed in this study may represent selective testing in anticipation of vaccine series initiation or missed documentation of vaccination. Among unvaccinated CHC patients tested for anti-HBs or anti-HBc, 55% tested positive to 1 or both. As an indicator of prior hepatitis B exposure, 75% of those testing positive for anti-HBs also tested positive for anti-HBc. The cost effectiveness of testing prior to vaccination is largely dependent on the prevalence of prior vaccination and lifetime risk of infection. The high levels of coinfection observed in our CHB and CHC patients suggest that many of the untested patients are actually protected and that prescreening followed by vaccination of antibody-negative patients would be cost effective for both hepatitis A and hepatitis B vaccines [32, 33] .
Our study has several strengths, including the mean followup of >5.5 years since hepatitis B or hepatitis C diagnosis and 8 years of plan membership. Because patients were plan members, laboratory tests and results and vaccination administration records should be captured in the electronic health record. The previous VA studies nearly exclusively included men (97%), whereas our population-based study is geographically and ethnically diverse and includes women.
As we previously discussed, many of the untested patients will be protected due to past exposure to infection or prior vaccination. One limitation of our vaccine history assessment is that some patients with positive anti-HA will have had prior vaccinations not captured in the electronic health record. This would have been more likely at Geisinger and Henry Ford, where we relied on billing and claims data for documentation of vaccine administration. Because the 2 Kaiser Permanente sites include data from immunization registries as well as information capture during encounter, we would expect better capture of vaccinations. In contrast, we considered a single vaccine as immunity inducing, which could overestimate the number protected by an estimated 27% for hepatitis A vaccine, although we observed high completion rates (70%) in our CHC population, which confers immunity in >90% of CHC patients [6] . There is less evidence that a single hepatitis B vaccine is adequate, considering that 31% of CHC patients in a German vaccine trial and 44% of CHC patients in an Italian vaccine trial did not respond to a full hepatitis B series [24, 25] . Due to the observational nature of the study, we do not have a full set of preand postvaccine tests to fully assess immunity.
In summary, the presently reported US population-based estimates demonstrate that a substantial proportion of patients with chronic viral hepatitis remain susceptible to vaccinepreventable hepatitis A and hepatitis B infections. These data reinforce the observation that efforts are needed to improve both antibody testing and subsequent vaccination for vulnerable populations of chronic viral hepatitis patients. Given that CHB and CHC patients often do not receive optimal followup care, it may be appropriate to consider recommendations that target vaccination at diagnosis or before the development of more advanced fibrosis or cirrhosis.
